Iceland· IS-EU/1/15/1047/001
Blincyto
A blinatumomab product containing blinatumomabum inn, registered in Iceland by Amgen Europe B.V.*. The same ATC class is registered in 10 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Blinatumomab is registered in 10 of 19 countries.
Countries holding a registration under ATC L01FX07 (blinatumomab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Blinatumomab · ATC L01FX07
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of blinatumomab costs, country by country.
Normalised to the WHO defined daily dose (18.7 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Blinatumomab · price per daily dose (18.7 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$1422.57
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Blinatumomabum INN
- Manufacturer
- Amgen Europe B.V.*
- Country
- Iceland (IS)
- ATC code
- L01FX07
- ATC class
- Blinatumomab
- Defined daily dose
- 18.7 mcg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean1770991 hgl x1 pakkiISK 429241
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
139 interactions on record for blinatumomab.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Blinatumomab · interactions on record
139 records
- 37 severe
- 102 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Blinatumomab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandBlincytoOrifarm Oy
- NorwayBlincytoAmgen Europe B.V.
- SwitzerlandBlincyto
- CzechiaBLINCYTOAmgen Europe B.V., Breda
- SpainBlincyto 38,5mcg de polvo para concentrado y solucion para solucion para perfusionAmgen Europe B.V.
- FranceBLINCYTO 38,5 microgrammes, poudre pour solution à diluer et solution pour solution pour perfusionAMGEN EUROPE
- United KingdomBlincyto 38.5micrograms powder for concentrate and solution for solution for infusion vialsAmgen Ltd
- IrelandBLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusionAmgen Europe B.V.,
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Norway · Blincyto
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d1391984-9b36-4d07-b59b-a84051144ea3 GET /v1/drugs/d1391984-9b36-4d07-b59b-a84051144ea3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stofn fyrir innrennslisþykkni, lausn og lausn fyrir innrennslislyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FX07",
"marketed": true,
"strength": "38,5 míkróg",
"ma_number": "EU/1/15/1047/001",
"substance": "Blinatumomabum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "42361"
}See everything about blinatumomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.